论文部分内容阅读
目的:观察中药黄斑明目颗粒防治实验性高眼压所致大鼠视网膜缺血-再灌注损伤的疗效观察。方法:所有大鼠随机分为正常对照组、模型组、黄斑明目颗粒组。经前房恒压灌注生理盐水60 min,建立视网膜缺血-再灌注损伤的动物模型。黄斑明目颗粒组于造模前7 d开始予以黄斑明目颗粒灌胃给药,正常对照组及模型组给予等量生理盐水灌胃。观察缺血-再灌注损伤后1、7、14、28 d各组视网膜电图中a波及b波的变化,分析视网膜厚度,并进行视网膜电镜检查,结果:正常对照组大鼠不同时间点ERG的潜伏期和振幅无显著性差异;缺血-再灌注损伤后,模型组大鼠ERG的潜伏期和振幅均呈持续性、进行性下降,黄斑明目颗粒组大鼠ERG的潜伏期和振幅较模型组有显著改善(P<0.05),但仍差于正常对照组。眼病理试验结果表明,与模型组比较,黄斑明目颗粒组缺血-再灌注所致的大鼠视网膜损伤显著减轻。结论:黄斑明目颗粒对视网膜缺血-再灌注损伤有保护作用,是治疗视网膜缺血性疾病的有效中药复方制剂。
OBJECTIVE: To observe the curative effect of traditional Chinese medicine Huangma Mingmu Granules in preventing and controlling retinal ischemia-reperfusion injury induced by experimental ocular hypertension in rats. Methods: All rats were randomly divided into normal control group, model group, macular eyesight granules group. After the anterior chamber was infused with saline for 60 minutes, an animal model of retinal ischemia-reperfusion injury was established. The macular eyesight granule group was administrated macular eyesight granules 7 days before the model making, the normal control group and the model group were given the same amount of normal saline. The changes of a-wave and b-wave in the electroretinograms of each group were observed at 1, 7, 14 and 28 days after ischemia-reperfusion injury. The retinal thickness was analyzed and examined by electron microscopy. The results showed that the ERG There was no significant difference in latency and amplitude between two groups. After ischemia-reperfusion injury, the latency and amplitude of ERG in model group were both persistent and progressive, and the latency and amplitude of ERG in model group were higher than those in model group (P <0.05), but still worse than the normal control group. Eye pathology test results showed that, compared with the model group, the macular eyesight particles group ischemia-reperfusion-induced retinal damage was significantly reduced. Conclusion: Macula macular granules have a protective effect on retinal ischemia-reperfusion injury and is an effective traditional Chinese medicine preparation for the treatment of retinal ischemic diseases.